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A B S T R A C T
Complete DiGeorge syndrome (CDGS) has a severe T-cell immunodeﬁciency and is fatal without thymus or bone
marrow transplantation. Associated congenital heart disease (CHD) further complicates the clinical management.
We report an infant with tetralogy of Fallot, conﬂuent and hypoplastic pulmonary arteries, right aortic arch, and
aberrant left subclavian artery. He was athymic with no CD3+ T cells. CDGS was diagnosed with 22q11.2 deletion.
The patient underwent central aortopulmonary shunt at 12 days of age. The patient died at 5 weeks of age awaiting
thymus transplantation. We performed a review of the literature regarding CDGS and CHD. We found 43 cases
including conotruncal defects (20) and nonconotruncal defects (23). The overall mortality rate was 67%. Among 30
cases undergoing transplantation (bone marrow 16 and thymus 12, bone marrow + thymus 2), the mortality rate was
53%. The patients with conotruncal defects were more likely to die before transplantation (45% vs. 16%, P = .04).
The main cause of death was infection before and after transplantation. We conclude that children with CDGS and
CHD have a high mortality. Bone marrow and thymus transplantation can improve the survival, but the overall
management of these high risk patients remains challenging.
Key Words. Tetralogy of Fallot; Complete DiGeorge Syndrome; Congenital Heart Disease; Thymus Transplanta-
tion; Bone Marrow Transplantation
Introduction
Complete DiGeorge syndrome (CDGS) is anextremely rare and profound T-cell immuno-
deﬁciency disease with a poor prognosis.1 Recently,
thymus and bone marrow transplantation has been
reported as a treatment option for CDGS.2,3 About
half of the cases with CDGS have congenital heart
disease (CHD) requiring surgery.3 Children with
bothCDGSandCHDremain at high risk and their
clinical management is challenging. We report an
infant with tetralogy of Fallot (TOF), who was also
diagnosed as CDGS. We reviewed the literature
regarding CDGS and CHD.
Case Report
A term infant with a prenatal diagnosis of TOF
was born with a birth weight of 2.9 kg to a
35-year-old mother who has history of repaired
TOF and a heterozygous Factor V Leiden deﬁ-
ciency. Apgar score was 8 at 5 minutes. He was
started on prostaglandin E1 infusion at birth. He
had a dysmorphic face characterized by low set and
anteriorly rotated ears, ocular hypertelorism, as
well as bilateral inguinal hernia. Echocardiogram
conﬁrmed the prenatal diagnosis of TOF with a
hypoplastic pulmonary valve, but the anatomy of
pulmonary arteries was unclear. A cardiac cath-
eterization was performed at 3 days of age. There
were conﬂuent and hypoplastic pulmonary arter-
ies, a right aortic arch and aberrant left subclavian
artery with two small collateral arteries arising
from the aberrant left subclavian artery to the
branch pulmonary arteries (Figure 1). There was
no evidence of a patent ductus arteriosus. Prostag-
landin E1 was discontinued.
The 22q11.2 deletion was detected by ﬂuores-
cence in situ hybridization. Immunology consul-
tation was made because of lymphopenia (0.9 ¥
109/L). Flow cytometry revealed 0% CD3+ T
cells, 60% CD19+ B cells (0.54 ¥ 109/L), and 25%
natural killer (NK) cells (0.225 ¥ 109/L). Immuno-
globulin G, A, and M were 660, <7, and 8 mg/dL,
respectively. Serum calcium was 6.5 mg/dL with
intact parathyroid hormone (PTH) <1 IU/mL,
which was consistent with hypocalcemia second-
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ary to hypoparathyroidism. The diagnosis of
CDGS was made. He was kept in a negative pres-
sure isolation room and started on antibiotic
prophylaxis with sulfamethoxazole–trimethoprim.
His persistent hypocalcemia was controlled with
oral calcium supplements and calcitriol. One
dose of intravenous immunoglobulin (IVIG was
given at 3 weeks of age. He was referred to an
outside institution for possible thymus transplan-
tation. Surgical systemic-pulmonary shunt was
pursued to establish more reliable source of pul-
monary blood ﬂow because of persistent systemic
desaturation, before the transfer for thymus
transplantation.
At 12 days of age, he underwent a 4-mm central
aortopulmonary shunt. The pathology of tissue in
the thymus area was reactive lymph nodes with no
thymus tissue present. Intraoperative inspection
discovered unique coronary artery anatomy. A
large branch from the right coronary artery
coursed right along the annulus and then inserted
into the left anterior descending artery. It
appeared that a single left anterior descending
artery was fed by two different branches. Electro-
cardiographic ischemic change was noted with
transient occlusion of this accessory branch. This
unique anatomy would preclude the future use of a
transannular patch. The postoperative course was
complicated with a sternal wound dehiscence and
postpericardiotomy syndrome which was treated
with steroids. He was going to be discharged with
scheduled thymus transplantation. He developed
acute respiratory distress after an episode of emesis
at 4 weeks of age. Chest radiograph showed right
lower lobe opacity. Vancomycin and cefepime
were started for suspected aspiration pneumonia.
Seven days later, he suddenly developed cardiop-
ulmonary failure and expired.
Autopsy was obtained with his parental consent.
The central aortopulmonary shunt was patent.
A B C
D E F
Figure 1. Angiographic images at 3 days old. The 4-Fr pigtail catheter is in the ascending aorta (A) and descending aorta
(B) in the AP view. There is a right aortic arch with an aberrant left subclavian artery arising from descending aorta. Note no
patent ductus arteriosus or coarctation of the aorta. Two small collateral arteries arise from the aberrant left subclavian artery
to branch pulmonary arteries. Selective injection in the aberrant left subclavian artery shows collateral arteries connecting
to each pulmonary artery branch respectively in AP (C) and lateral (D) view. Left lower pulmonary vein wedge injection shows
the confluent and hypoplastic pulmonary arteries in AP (E) and lateral (F) view.
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The interstitial ﬁbrosis and early myocyte damage
with contraction bands suggested recent and
remote episodes of ischemia. No evidence of
pneumonia was noted with mild to moderate
intimal ﬁbrosis of small pulmonary arteries. Post-
mortem lung and blood cultures grew mixed
Enterococcus faecium and Psuedomonas ﬂuorescens, felt
to be due to postmortem contamination.
Discussion
DiGeorge syndrome is a clinically heterogeneous
disease, characterized by cardiovascular defects,
thymus, parathyroid, and craniofacial anomalies,
and is caused by developmental defects in the third
pharyngeal pouch and fourth pharyngeal arch.4
Most cases of DiGeorge syndrome are caused
by chromosome band 22q11.2 deletion.5 A
chromodomain-helicase-DNA-binding protein 7
(CHD7) mutation has been recently reported in
patients with CDGS.6 Thymus defects occur in
~80% of patients with DiGeorge syndrome,
leading to varying degrees of cellular immunode-
ﬁciency.1 CDGS describes a rare subset of children
with the clinical features of DiGeorge syndrome
and severe T-cell immunodeﬁciency, which is fatal
without intervention within the ﬁrst 2 years of
life.1 Our patient had TOF, 22q.11.2 deletion, and
no detectable CD3+ T cell, consistent with CDGS.
Intraoperative inspection revealed no thymus.
The incidence of TOF, including TOF with
pulmonary atresia, is present in 10–21% of
patients with 22q11.2 deletion.5 The study of
545 patients with 22q11.2 deletion showed the
presence of TOF in 17%, pulmonary atresia/
ventricular septal defect in 10%, ventricular septal
defect in 14%, interrupted aortic arch in 14%, and
truncus arteriosus in 9%.7 Our patient had right
aortic arch, conﬂuent and hypoplastic pulmonary
arteries, collateral arteries from the aberrant left
subclavian artery to branch pulmonary arteries,
without a patent ductus arteriosus. There was a
unique coronary artery anomaly which would pre-
clude the use of a transannular patch. Two small
collateral arteries arose from the aberrant left sub-
clavian artery. A central aortopulmonary shunt was
elected because a modiﬁed Blalock–Taussig shunt
was deemed not suitable for hypoplastic branch
pulmonary arteries.
Thymus transplantation and bone marrow
transplantation for CDGS are promising immune
reconstitution therapies with reasonable out-
comes.2,3,8,9 Janda et al. reported 17 patients with
CDGS who underwent transplantation of hemato-
poietic cells.2 The overall survival rate was 41%
with a median follow-up of 5.8 years. Among 12 of
17 patients having CHD, nine patients (75%) died
after transplantation. Markert et al. reported 54
patients with CDGS who were enrolled in proto-
cols for thymus transplantation.3 Among 44
patients undergoing thymus transplantation, 33
(75%) survived with a median follow-up of 3 years
and 10 months. Thirty-one (57%) of 54 subjects
had CHD requiring surgery. Seventeen subjects
had conotruncal defects including eight with TOF.
Although the survival of patients with CHD was
not reported, authors mentioned that infants with
CDGS continued to die of cardiac complications
and infections.
We performed a review of the literature regard-
ing CDGS with CHD.1–3,6,8,10–19 We included cases
in which a detailed CHD diagnosis is available
with severe immunodeﬁciency consistent with
CDGS. A total of 43 cases (including ours) were
reported and can be categorized into two groups:
(1) conotruncal defects, n = 20; and (2) non-
conotruncal defects, n = 23 (Table 1). The
conotruncal defects group consisted of TOF 11,
truncus arteriosus 4, interrupted aortic arch 2,
double outlet right ventricle and interrupted aortic
arch 1, truncus arteriosus and interrupted aortic
arch 1, and nonspeciﬁed 1. The nonconotruncal
defects group consisted of the combination of the
following diagnoses: ventricular septal defect,
atrial septal defect, atrioventricular septal defect,
patent foramen ovale, coarctation of aorta, right
aortic arch, aberrant subclavian artery, and aortic
arch anomaly. With the median age of 14 months
(range, 5 weeks to 24 years) at the last follow-up,
the overall mortality was 67% (28/42). No patients
survived without transplantation. The mortality
rate was comparable between the conotruncal and
nonconotruncal group (75% vs. 64%, P = .514).
The major cause of deaths was infection in the
whole group before and after transplantation. The
22q11.2 deletion and CHD7 gene mutation were
documented in 44% and 14%. Findings consistent
with CHARGE syndrome were seen in 30%. The
cardiac repair was performed in 64% (18/28).
Transplantation was performed in 70% (30/43) at
a median age of 107 days (range, 33 days to 13
months). The type of transplantation included
bone marrow 16, thymus 12, and bone marrow +
thymus 2. In the patients undergoing transplanta-
tion (n = 30), the mortality rate was 53% at the
median follow-up duration after the ﬁrst trans-
plantation of 17 months (range, 107 days to 24
years). In the conotruncal group (n = 20), 11
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underwent transplantation and six died later. In
nine patients who died before transplantation, six
underwent palliative or deﬁnitive cardiac repair. In
the nonconotruncal group (n = 23), 19 underwent
transplantation and three died afterward. The
patients with conotruncal defects were more likely
to die before transplantation (45% vs. 16%, P =
.04). Among 14 patients who survived after trans-
plantation, eight (57%) had a signiﬁcant morbidity
such as developmental delay, speech delay, and/or
pharyngeal and gastrointestinal problems. The
timing between transplantation and cardiac repair
can not be assessed because of limited reported
data. This review of the literature suggests that
children with both signiﬁcant CHD and CDGS
remain at high risk for morbidity and mortality,
even after bone marrow or thymus transplanta-
tion. Although the survival rate after transplanta-
tion is lower in children with CDS and CHD as
compared to those without CHD, about half of
children may survive if their CHD can be treated
adequately with successful transplantation.
Conclusion
We report a rare case of CDGS and TOF. Unfor-
tunately, the infant expired after a central
aortopulmonary shunt while awaiting thymus
transplantation. Review of the literature suggests
that children with CDGS and CHD have a high
mortality and morbidity. Conotruncal defects have
a high mortality before transplantation. Bone
marrow and thymus transplantation can improve
the survival, but the overall management of these
high risk patients remains challenging.
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